Back to top

medical-devices: Archive

Zacks Equity Research

MMSI Stock Gains Following Latest Merger to Boost Hemostasis Portfolio

Merit Medical aims to provide an additional effective solution that complements a wide range of percutaneous procedures, including interventional radiology and cardiology.

MMSINegative Net Change CORNegative Net Change ITGRNegative Net Change HIMSNegative Net Change

Zacks Equity Research

FONR Stock Rises Following Q3 Earnings on Higher Net Income

FONAR Corporation's Q3 fiscal 2025 results show higher net income and revenue growth, driven by record MRI scan volumes and strong performance of its HMCA unit.

FONRPositive Net Change

Indrajit Bandyopadhyay

4 Medical Product Stocks to Watch From a Challenging Industry

The U.S. government's tariff imposition, especially on China, is likely to keep supply chains under pressure for the Zacks Medical Products industry. PODD, MGNX, CLRB and ALUR reflect the favorable fundamentals.

PODDNegative Net Change MGNXNegative Net Change CLRBPositive Net Change ALURNegative Net Change

Zacks Equity Research

AST Business Growth & Strategic Acquisitions Support STERIS Stock

STE frequently engages in strategic acquisitions and joint ventures to optimize its portfolio of businesses.

PBHNegative Net Change STENegative Net Change PAHCNegative Net Change HIMSNegative Net Change

Zacks Equity Research

BAX Stock May Rise Following the Launch of FDA-Approved Hemopatch Pad

Baxter launches Hemopatch Sealing Hemostat, an FDA-approved collagen pad designed for effective hemostasis and sealing in both open and minimally invasive surgeries.

ANGOPositive Net Change BAXNegative Net Change CVSNegative Net Change ITGRNegative Net Change

Zacks Equity Research

Reasons to Retain QuidelOrtho Stock in Your Portfolio for Now

QDEL continues to witness growth on the back of its strong product portfolio.

ANGOPositive Net Change CVSNegative Net Change QDELNegative Net Change ITGRNegative Net Change

Zacks Equity Research

What's Driving Quest Diagnostics Stock's 25.6% Rally in a Year?

DGX has shown notable strength in the past year, driven by robust core performance and contributions from acquisitions.

DGXNegative Net Change PBHNegative Net Change PAHCNegative Net Change INSPNegative Net Change

Zacks Equity Research

Here's Why You Should Retain Glaukos Stock in Your Portfolio

GKOS continues to benefit from robust product demand and expansion in new markets. A strong development pipeline raises optimism.

CVSNegative Net Change CORNegative Net Change GKOSNegative Net Change WGSNegative Net Change

Zacks Equity Research

Vaso Stock Slips Post Q1 Earnings Despite Record Revenue Growth

VASO's first-quarter 2025 revenues hit a record high, but a narrowed net loss and muted stock reaction highlight investor caution despite solid segment growth.

VASOPositive Net Change

Zacks Equity Research

SYK Stock Likely to Rise Following FDA Clearance for OptaBlate System

Stryker secures FDA clearance for OptaBlate BVN, a groundbreaking nerve ablation system designed to treat chronic vertebrogenic lower back pain with precision and safety.

ANGOPositive Net Change SYKNegative Net Change CVSNegative Net Change ITGRNegative Net Change

Zacks Equity Research

Should You Continue to Hold Charles River Stock in Your Portfolio?

CRL stays on investors' radars due to the strength of partnerships and segmental prospects.

CRLNegative Net Change PBHNegative Net Change PAHCNegative Net Change INSPNegative Net Change

Zacks Equity Research

Illumina Stock to Gain From the Launch of New DRAGEN v4.4 Software

ILMN's latest software features easy-to-use oncology apps, enhanced multiomics pipelines and AWS F2 support, enabling faster turnaround times.

ILMNNegative Net Change PBHNegative Net Change PAHCNegative Net Change HIMSNegative Net Change

Zacks Equity Research

Cooper Companies Q2 Earnings Likely to Reflect Seasonal Trends

COO's fiscal second-quarter results are expected to follow seasonal trends, with a lighter start compared to the previous two reported quarters.

LHNegative Net Change MCKNegative Net Change XRAYNegative Net Change COONegative Net Change

Zacks Equity Research

BD Stock May Rise Following the Launch of FACSDiscover A8 Platform

BDX unveils the BD FACSDiscover A8, a next-gen cell analyzer with spectral flow cytometry and real-time imaging, enabling deeper insights into cell function and biology.

ANGOPositive Net Change BDXNegative Net Change CVSNegative Net Change ITGRNegative Net Change

Zacks Equity Research

ZBH Stock to Gain From Buyouts and Innovations Amid Macro Issues

Zimmer Biomet is strategically expanding its global presence to address the huge demand in the musculoskeletal space.

BSXNegative Net Change CAHNegative Net Change ZBHNegative Net Change HIMSNegative Net Change

Zacks Equity Research

Abbott Reveals Positive Outcome From REFLECT Studies, Stock Climbs

Per REFLECT studies, ABT's Libre technology is the first CGM linked to fewer hospitalizations for heart complications in people with diabetes.

ABTNegative Net Change BSXNegative Net Change CAHNegative Net Change HIMSNegative Net Change

Zacks Equity Research

Here's Why You Should Add Hims & Hers Stock to Your Portfolio Now

Hims & Hers leads with AI-powered, personalized health plans (over 70% of new users opt in). Recurring revenues surge as tailored care drives loyalty.

CVSNegative Net Change CORNegative Net Change HIMSNegative Net Change WGSNegative Net Change

Indrajit Bandyopadhyay

MCK Stock Gains More Than 4% Following Strong Q4: Should You Buy Now?

McKesson's strong fundamentals are likely to keep it ahead of the competition. Should investors add it to their portfolio now?

CAHNegative Net Change MCKNegative Net Change CORNegative Net Change

Debanjana Dey

Hims & Hers Stock Declines 3.1% in 3 Months: Is it a Buy Now?

HIMS is expanding its health and wellness products and services and increasing its focus on AI to solidify its footing. However, macro challenges may hurt performance.

ABTNegative Net Change TDOCNegative Net Change HIMSNegative Net Change

Zacks Equity Research

Here's Why You Should Retain Ecolab Stock in Your Portfolio Now

ECL continues to gain from its robust product portfolio and strong segmental performance.

ECLNegative Net Change ANGOPositive Net Change CVSNegative Net Change ITGRNegative Net Change